StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities researchers at StockNews.com began coverage on shares of Minerva Neurosciences ( NASDAQ:NERV – Get Free Report ) in a research report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th. View Our Latest Report on Minerva Neurosciences Minerva Neurosciences Stock Down 1.



9 % Minerva Neurosciences Company Profile ( Get Free Report ) Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. See Also Five stocks we like better than Minerva Neurosciences How is Compound Interest Calculated? Super Micro Computer Soars 28%: Is It Really Out of the Woods? Low PE Growth Stocks: Unlocking Investment Opportunities Traders Are Flocking Back to Oil: What’s Fueling the Optimism Stock Market Upgrades: What Are They? 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.

com's FREE daily email newsletter ..